SCHEMBL29848847

SCHEMBL29848847

O=[N+]([O-])c1ccc2[nH]c(-c3ccc(Cl)c(C(F)(F)F)c3)nc2c1

nearest known ligand 0.57

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NPBWR1 P48145 13/20 0.57
MAPT P10636 6/20 0.54
RAB9A P51151 6/20 0.54
NPC1 O15118 6/20 0.54
SMN1; SMN2 Q16637 5/20 0.54
HTT P42858 4/20 0.54
MEN1 O00255 3/20 0.54
KMT2A Q03164 3/20 0.54
ALDH1A1 P00352 2/20 0.54
LMNA P02545 1/20 0.54
HPGD P15428 1/20 0.54
MMP2 P08253 2/20 0.52
MMP9 P14780 2/20 0.52
MMP8 P22894 2/20 0.52
CASP3 P42574 2/20 0.52
SENP8 Q96LD8 2/20 0.52
SENP7 Q9BQF6 2/20 0.52
SENP6 Q9GZR1 2/20 0.52
MMP13 P45452 1/20 0.52
L3MBTL1 Q9Y468 1/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3190872 0.86 NPBWR1 (0.65) NPBWR1MAPTRAB9ANPC1SMN1; SMN2
SCHEMBL986164 0.82 NPBWR1 (0.45) NPBWR1MAPTRAB9ANPC1SMN1; SMN2
SCHEMBL3193088 0.80 NPBWR1 (0.80) NPBWR1MAPTRAB9ANPC1SMN1; SMN2
SCHEMBL5566197 0.80 NPC1 (0.78) NPBWR1MAPTRAB9ANPC1SMN1; SMN2
SCHEMBL29848557 0.80 MEN1 (0.52) MAPTRAB9ANPC1SMN1; SMN2HTT
SCHEMBL22981809 0.80 MEN1 (0.52) MAPTRAB9ANPC1SMN1; SMN2HTT
SCHEMBL3204647 0.79 RAB9A (0.60) NPBWR1MAPTRAB9ANPC1SMN1; SMN2
SCHEMBL29848496 0.79 SLC6A9 (0.49) NPBWR1MAPTRAB9ANPC1SMN1; SMN2
SCHEMBL29848643 0.79 CCNA2 (0.53) NPBWR1MAPTRAB9ANPC1SMN1; SMN2
SCHEMBL3183535 0.78 MAPT (0.66) NPBWR1MAPTRAB9ANPC1SMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12473278-B2 Imidazole derivative expressing FLT3 inhibitory activity, and use thereof INDUSTRY-UNIVERSITY COOPERATION FOUNDATION HANYANG UNIVERSITY ERICA CAMPUS (KR) 2025-11-18 US disclosed
US-20220315573-A1 Novel Imidazole Derivative Expressing FLT3 Inhibitory Activity, and Use Thereof Industry-University Cooperation Foundation Hangyang University Erica Campus (KR) 2022-10-06 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220315573-A1 Novel Imidazole Derivative Expressing FLT3 Inhibitory Activity, and Use Thereof FLT3, FLI1, MCL1 NPBWR1 4167/4885MAPT 4590/4885RAB9A 3734/4885
US-12473278-B2 Imidazole derivative expressing FLT3 inhibitory activity, and use thereof FLT3, FLI1, MCL1 NPBWR1 4128/4885MAPT 4520/4885RAB9A 3807/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.